ABSTRACT -Background -The pretransplant period is complex and includes lots of procedures. The severity of liver disease predisposes to a high number of hospitalizations and high costs procedures. Economic evaluation studies are important tools to handle costs on the waiting list for liver transplantation. Objective -The objective of the present study was to evaluate the total cost of the patient on the waiting list for liver transplantation and the main resources related to higher costs. Methods -A cost study in a cohort of 482 patients registered on waiting list for liver transplantation was carried out. In 24 months followup, we evaluated all costs of materials, medicines, consultations, procedures, hospital admissions, laboratorial tests and image exams, hemocomponents replacements, and nutrition. The total amount of each resource or component used was aggregated and multiplied by the unitary cost, and thus individual cost for each patient was obtained. $ 5,703.22 ± 9,318.68). Conclusion -Total costs on the waiting list for liver transplantation increased according to the patient's severity. Individually, hospitalizations, hemocomponents reposition and hepatocellular carcinoma treatment were the main cost drivers to the patient on the waiting list. The longer the waiting time, the higher the total cost on list, causing greater impact on health systems.
INTRODUCTION
More than 2 billion people around the world have been infected by hepatitis B (HBV) and C (HCV) virus, resulting in approximately 400 million patients with advanced end chronicle liver disease. For the next 30 years, around 15%-40% of them will develop cirrhosis, hepatic failure, and hepatocellular carcinoma (30, 34) . The annual expenditure with HCV and advanced liver disease comprises more than 32 billion dollars, with increases over time. The number of patients with viral hepatitis is growing annually and some stu dies estimated an increase of 60% of this amount in the next few years (14, 29, 35, 45) . The pretransplant period is complex and includes large quanti ties of procedures (19, 22) . To date, previous studies have shown that the increased severity of liver disease predisposes to a high number of hospitalizations, high costs procedures increased morbidity and a high number of deaths (12, 13, 41, 46) . Studies have shown that the cost of hospitalizations of patients with alcoholic cirrhosis overpass US$ 8 thousand each stay. The annual cost of health care in this patient can reach 848 million dollars in the USA annually (12, 13) . In
Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study Brazil , the annual cost of heath care of each patient with advanced liver disease can reach more than 20 thousand dollars (1, 2, 11, 27, 28, 38, 44, 49) . Some correlated disease has strong linkage with high costs procedures and hospitalizations. Hepatocellular carcinoma is a malignancy associated with a high rate of mortality and costs (4) . Hepatocellular carcinoma (HCC) currently, affects 1.5% of the world population and reach approximately 15% of patients on the waiting list for liver transplantation (1, 11, 21) . Mishra et al. (28) has demonstrated that the costs of treating patients with HCC in 2009 were around US$ 31 thousand, with total treatment costs of ap proximately US$ 2 billion in the USA.
Patient's severity, waiting time, highcost procedures and medications, and hospitalizationrelated complications increase the number of employed resources and consequently the patient's costs, making these expenses increasingly important in the sum total of costs of these patients (2, 14, 46) . The incorporation of new technologies has led to an exponen tial growth in health spending, resulting in increasing pressure for more efficient use of the limited resources available (2, 3, 36, 38) . Tan (40) has shown that differences in patient cost estimation parameters can lead to differences between € 855 and € 3221 in the cost per day with hospitalizations.
In studies carried out with microcosting methodology, all the relevant components and resources are individually raised to the highest level of detail possible (7, 9, 10, 23, 39) . This methodology increases the accuracy of the cost estimate and reflects the truthful use of the resources and their economic value through the detailed data collec tion of each resource used and the unit value of these resources (48) . Lack of detail, bias or underestimated analysis of costs may result in failures in the cost evaluation of diseases or programs under analysis with considerable implications (5) . There is a growing interest of governments and health systems in economic evaluation studies that can improve the way in which limited budget resources allocated to patient care are shared out (8, 15, 37, 42, 47) . Health technology assessment helps to achieve this purpose, making it possible to identify areas that require more in vestment and interventions associated with higher costs. The objec tive of this study was to determine the total cost of patients on the waiting list for liver transplantation and the resources that caused a greater impact on these costs, using microcosting methodology.
METHODS
This was a prospective cohort study that included all patients on waiting list for liver transplantation attended at Clinics Hospital, Sao Paulo Medical School (HCFMUSP) between January 2012 and December 2013. An economic evaluation study using micro costing methodology was carried out. The hospital perspective was taken in the measurement of resource use and costs by patients within the followup.
For each patient included in this study, patient demographics, clinical and overall cost were obtained. The amounts of resources (in units) were obtained using datasheet developed specifically for this study and individual data for each patient were registered. The followup period was individually calculated by the inclusion date of the listed patient until one of the following outcomes: list removal for improvement or worsening of the clinical health status, death, hospitalization for transplantation or completion of the study.
The MELD (Model of EndStage Liver Disease) values were calculated for each patient on the day of enrollment and on the first day of hospitalization using the logarithmic formula of the results of the creatinine, total bilirubin, and INR tests. Four groups of patients were formed according to their MELD score severity based on the quartiles. This approach was carried out to better separate the groups with fewer outliers values and reach a better homogeneity intra quartiles.
The amounts of resources were directly obtained from differ ent care sectors.
The total amount of medication used per patient was obtained by the hospital pharmacy sector through a computerized prescrip tion system and a number of materials used were obtained from a data sheet developed for this study and filled in by the Nursing Service during the patient's hospitalization. The quantities of labo ratory tests and imaging were obtained directly in the electronic patient's database. The total number of consultations performed by medical and nonmedical professionals was obtained directly from the electronic database of each patient. Regarding nutrition, the total quantities of diets received were obtained directly from the patient's electronic database by medical prescription. The total amounts of paracentesis, flasks, and albumin used per patient were provided directly by the nursing service of this sector. The amounts of dialysis performed were obtained from the patient's electronic database. The total amount of blood bags received per patient in hospitalizations were obtained directly in the electronic medical database of the hospitalized patient.
Cost data
The costs of each resource represent the costs of purchasing inputs and services by the hospital and do not represent the "full" price practiced by the pharmaceutical service or other market research inputs. Indirect costs were not included in this study. All costs were added together for the calculation of total cost per patient. Resources were divided into outpatient costs and hospi talization costs.
Outpatient costs included all services related to medical, dental, psychological, nutritional, nursing and social service consultations per patient were quantified and analyzed. We also considered the costs of procedures such as paracentesis and dialysis, materials, medicines, laboratory and imaging tests. Inpatient charges included all costs related to materials, medications, laboratory and imaging exams, procedures performed, blood transfusions, the length of stays and costs related to nursing and ICU diaries were quantified and analyzed.
The cost values of medication and materials were obtained from the Materials Administration System (MAS), where updated values of the last trading sessions paid for each item are recorded. The cost values of each image examination were obtained from the specialized department of each sector. The cost values of each laboratorial test were obtained at the hos pital's central laboratory. Human resources costs were obtained directly from the administrative and managerial sector of the hospital and were calculated by the total amount of the wages received (including vacations, 13th salary, premiums, overtime surcharges, and withdrawals, etc.) divided by the total number of visits monthly and by the time spent in each service. The values of each type of enteral diet were determined by the Division of Nutrition and the values for parenteral diets were determined by the Division of Pharmacy. The values of each resource used for paracentesis, ambulatory dialysis and dialysis in hospitalization were provided by the Material Administration System (MAS) and directly by the department responsible for the procedure. The values of each blood component were obtained directly from the Hemotherapy Department through the administrative systems of cost management in this sector.
Procedures related to the treatment of hepatocellular carci noma were obtained directly from the Institute of Cancer of the State of Sao Paulo (ICESP) using the methodology of absorption costing. The amounts of procedures performed and the costs were provided by the electronic databases of this hospital and are related to all resources and services used for each procedure, human resources, materials and related drugs and divided by the number of patients attended.
The total number of hospital bed days were obtained directly in the patient's electronic database and included the number of days in the ward and in the ICU for each patient. The calculation of the cost of daily hospital bed included amounts spent by the sector on human resources, specialized cleaning services, cloakroom sterilization, electric power, medical gasses and telephone calls. The total cost was obtained and values of bed use were calculated and divided for the number of patients attended.
Statistical analysis
Statistical analysis was performed using the R software version 3.3.1 (33) . In all cases, the level of significance considered was 5%. The categorical data were presented in percentages and the cost data were presented in averages, standard deviations, and ranges.
To analyses the cost differences by the MELD groups was per formed using the ANOVA test for variables that follow a normal distribution (AndersonDarling test) and for variables that do not follow normality, the KruskalWallis test. The assumption of Normality was verified by AndersonDarling test and homogeneity of variances by Levene test. Multiple comparisons were done by Tukey's parametric and nonparametric tests.
For comparative analysis, in addition to the total values, the costs per day (total cost/day) and the costs per day in hospitaliza tion (hospitalization cost/day) were also presented.
RESULTS
In this study, 482 patients were regularly included on the waiting list for liver transplantation. Among them, 134 patients were trans planted (27.8%), 103 patients were removed from the list (21.4%), 66 patients died (13.9%) and 179 patients (36.9%) remained on the list until the end of the study.
The most frequent etiology was cirrhosis caused by hepatitis C virus (HCV) in 187 patients (38.8%), followed by alcoholic cirrho sis in 152 (31.5%). There were 301 male patients (62.4%) and 181 female patients (37.6%). There were 277 patients requiring hospi talizations (69.25%), with 412 admissions in total and an average of 1.4 hospitalizations per patient. The clinical and demographic data of patients divided by MELD group, procedures performed, wai ting time and numbers of hospitalizations are presented in Table 1 .
Patients were divided into four groups by MELD score to verify the differences in cost. 132 patients had MELD below or equal to 17 (27 In this way, the cost/day related to each MELD group shows the relationship between the severity of disease and the costs over the time. We found that the more severe the patient, the greater its cost. The highest cost/day was found in those patients who had MELD >30 (US$ 566.33±1,083.92) followed by those with MELD 2530 (US$ 167.29±330.52). The total average cost per patient for each MELD score group are shown in Table 4 .
DISCUSSION
Patients on the waiting list for liver transplantation are subject to a series of complications and intercurrences that lead to the need for hospitalizations and procedures that increase the costs of care (17) . This is the first prospective cohort study that has used a microcosting methodology for the analysis of the total cost of patients on the waiting list for liver transplantation. Most studies, to date, do not address the patient's total costs, and these high costs cannot be overlooked (2) . A standard methodology in microcosting was used so that accuracy of each patient costs was improved. This procedure in tended to ensure that the cost differences were related to real clinical practice and not to data acquisition failures or general averages.
In our study, we found that more severe patients have a subs tantially higher cost than less severe patients. Studies addressing the relationship between patient costs and MELD have already pointed to this causal relationship (18, 46) . We also found that high costs are the result of a series of complications and intercurrences that lead to a greater number of hospitalizations and highcost procedures (13, 17, 20) . Although the total cost of patient care in our study was con sidered low, averaging just over US$ 12,000, compared to studies showing the annual cost of about US$ 20,000 in HCV patient care, we found that the cost of treating the most severely ill patient may exceed the costs of liver transplantation (26, 30) . Currently, the manage ment of the patient in the list is aimed at maintaining the patient's health until the moment of transplantation and more effective and preventive actions can reduce the number of complications and hospitalizations.
Hemocomponents are a vital but expensive resource with a high increase in total cost. In patients with MELD >30, this cost is approximately 22% of the total cost and five times higher than in patients with MELD <=17. Studies addressing the cost of replacement of blood components are rare, however we observed in a recent study that the cost of the blood component per bag in Brazil (approximately US$ 300) is similar to values found in other studies, ranging from US$ 210 to US$ 338 (6, 16, 24, 43) . Coelho et al. showed that the replacement of blood components represented about 41% of the total cost (6) . In our study, the cost of human resources was 15% in the out patient clinic and 26% in hospitalizations, similar to other public hospitals in Brazil (32) . McAdam found costs related to human re sources to be 19.8% and 23.3% of total costs (26) . In another study, Oroz mentions that 32% to 44% of total costs are related to human resources, in the United States and OECD countries respectively (31) . Materials and drugs accounted for 9.9% and 26.8% respectively of the total costs per patient. The use of highcost drugs for the treatment of the patient in the list raises the costs of this resource. In developed countries, this value represents a lower percentage in relation to the total costs per patient, between 12.5% and 13.7% with unstable cirrhosis and CHC patients, respectively (26) . Treatment of patients with hepatocellular carcinoma causes a large impact on the total cost of these patients, with an average of US$ 7700 (the second most relevant resource in total costs). In other studies, this figure reaches US$ 20,000 per year (25) . Despite the high cost, treatment of hepatocellular carcinoma is a costeffective procedure, recommended for the cure and withdrawal of the patient from the waiting list for transplantation, in other settings (25) . Patients with MELD 2530 accounted for 31.6% of the total costs, 51% of all costs in HCC management, 43.2% of the total expenditure in image exams and 32.2% of all costs in laboratorial tests. These MELD group patients had 2.0, 2.2 and 75.4 times higher costs related to HCC management than those with MELD >30, 1824 and <=17 respectively.
Patients with MELD >30 accounted for 30.7% of the total costs, 33.5% of hospitalization costs, 56.8% of costs with blood components, and 34.3% of drug costs. These MELD patients had 2.6, 3.4 and 11.6 times higher costs related to replacement of blood components when compared to patients with MELD 2530, 1824 and <=17 respectively.
The data presented in this study had some limitations that should be highlighted. All resources were calculated using the hospital costs, thus market values were not considered. This methodology can limit the comparison with other studies or with the costs of others hospitals. Furthermore, we decided not to use governmental reimbursement or similar tables of costs, because this could underestimate the cost data presented. The MELD value of each patient was calculated at the time of the inclusion on the waiting list or at the time of hospitalization. This procedure was necessary for the formation of MELD groups and posterior comparisons. The MELD evolution of each patient would be very difficult to perform in this study, but this is an important perspec tive for future studies.
When we analyzed the time length on the list, in relation to the cost/day and the total cost from each MELD score group, we found that the more severe patients remained less time on the list, but presented the highest cost/day. Considering the cost/day, patients with MELD >30 have cost/day 9.5 and 4.3 times more expensive than those with MELD <17 and 1824, respectively. Thus, it is possible to understand that, if the time on list of the more severe patients were longer, the total cost would be even higher, causing a high impact in the limited healthcare budgets.
Although, the data presented can be used as a subsidy for bet ter use of resources in the treatment of patients on the waiting list for liver transplantation and can provide important information, regarding frequency of complications, the percentage of resources and expenditures related to the severity of health status.
CONCLUSION
The patient's waiting list cost for liver transplantation increases as the patient's severity increases. Procedures related to the treat ment of the patient with hepatocellular carcinoma, the use of blood components and hospitalizations are the main cost drivers for the health care of these patients. As costs increase through time, it is also expected that the longer the time on waiting list, the higher the total costs and higher will be the economic impact in the limited healthcare budgets.
